Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial

Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target.

The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning.

Eli Lilly‘s stock rose 2.1% in premarket trading.

Novo is exploring additional trials to test CagriSema, including higher-dose combinations, it said.

This is breaking news. Please refresh for updates.

Source

World

Treasury yields hold steady as investors weigh new Trump tariffs

February 23, 2026

U.S. Treasury yields were little changed to start the week as investors weighed President Donald Trump’s latest tariffs, after the Supreme Court struck down much of the duties on Friday. At 6:03 a.m. ET, the 10-year Treasury yield was down 1 basis point at 4.075%. The 30-year Treasury bond yield was also less than 1 basis point lower […]

World

Sam Altman defends AI resource usage: Water concerns ‘fake,’ and ‘humans use energy too’

February 23, 2026

OpenAI CEO Sam Altman on Friday defended the resource demands of artificial intelligence, calling concerns about data centers’ water use “fake” and comparing the energy used by AI systems to that of humans. Altman was speaking on the sidelines of the India AI Impact summit in an interview with The Indian Express when he was […]

World

CNBC Daily Open: New Trump tariffs are up after U.S. Supreme Court strikes some down

February 23, 2026

U.S. President Donald Trump speaks during the National Governors Association Evening Dinner and Reception in the East Room of the White House on February 21, 2026 in Washington, DC, U.S. Al Drago | Getty Images News | Getty Images The U.S. Supreme Court on Friday struck down much of President Donald Trump’s “reciprocal” tariffs, which […]